

Supporting information

S3 Table Physiological measurements of endogenous DA in humans.

Source	Tonic level	partial depletion	tracer	method
[1]	72 ± 40 nM *)	70%	[¹²³ I]IBMZ	SPECT
[2]	23 ± 18 nM *)	70%	[¹²³ I]IBMZ	SPECT
[3]	27 ± 6 nM **)	not reported	[¹¹ C]raclopride	PET

References

1. Laruelle Marc, D'Souza Cyril D, Baldwin Ronald M, Abi-Dargham Anissa, Kanes Stephen J, Fingado Christine L, et al. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans. *Neuropsychopharmacology*. 1997;17:162. doi:[https://doi.org/10.1016/S0893-133X\(97\)00043-2](https://doi.org/10.1016/S0893-133X(97)00043-2) 10.1016/S0893-133X(97)00043-2.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. *Proceedings of the National Academy of Sciences*. 2000;97(14):8104–8109. doi:10.1073/pnas.97.14.8104.
3. Verhoeff NPLG, Kapur S, Hussey D, Lee M, Christensen B, C Psych , et al. A Simple Method to Measure Baseline Occupancy of Neostriatal Dopamine D2 Receptors by Dopamine In Vivo in Healthy Subjects. *Neuropsychopharmacology*. 2001;25:213. doi:[https://doi.org/10.1016/S0893-133X\(01\)00231-7](https://doi.org/10.1016/S0893-133X(01)00231-7) 10.1016/S0893-133X(01)00231-7.